Watch the replay of the webinar

 Advancing cardiac safety integrating new ICH E14/S7B Q&As best practices into in vivo QT assay

 

Recent evolution in E14/S7B guidelines expectations pave the way for a simpler and more powerful proarrhythmia risk assessments, with a true integration of preclinical and clinical data.

With more than 35 years of experience, Biotrial has developed significant expertise in translational research, bridging the gap between preclinical and clinical services. This vast experience guarantees high-quality, reliable, and innovative solutions in cardiac safety assessments, establishing Biotrial as an industry leader.

Design sans titre (9)
Eric Martel, 
Laboratory Head, Senior Principal Scientist General Pharmacology
at Boehringer Ingelheim

 

2
Jean-Pierre Valentin, 
Senior Director, Head of Investigative Toxicology
at UCB

 

4
Eric Delpy 
Scientific Director
at Biotrial
BIOTRIAL

 

3
Mathieu Grace 
Biometrics and Core Lab Product Manager
at Biotrial

 

Chapters

biotrial_webinar QT

  • Understanding ICH E14/S7B Q&As Guidelines

  • Case study: pharmacological and statistical sensitivity of the in vivo dog QT assay in line with ICH E14/S7B Q&As
    Integrated Preclinical and

  • Clinical proarrhythmia risk assessment